Q1 Revenue at $1.05B, Below Consensus of $1.07B
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 12h ago
0mins
Reports Q1 revenue $1.05B, consensus $1.07B.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like HOLX with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on HOLX
Wall Street analysts forecast HOLX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HOLX is 77.56 USD with a low forecast of 76.00 USD and a high forecast of 79.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
0 Buy
12 Hold
0 Sell
Hold
Current: 75.100
Low
76.00
Averages
77.56
High
79.00
Current: 75.100
Low
76.00
Averages
77.56
High
79.00
About HOLX
Hologic, Inc. is a medical technology company primarily focused on improving women's health and well-being through early detection and treatment. The Company is a developer, manufacturer and supplier of diagnostics products, medical imaging systems, and surgical products. Its segments include Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The Diagnostics segment offers a range of diagnostic products, which are used primarily to aid in the screening and diagnosis of human diseases. The Breast Health segment offers a broad portfolio of solutions for breast imaging, biopsy, breast surgery and pathology. The GYN Surgical segment's products include MyoSure hysteroscopic tissue removal system, NovaSure endometrial ablation system, Acessa ProVu laparoscopic radiofrequency ablation system, as well as CoolSeal vessel sealing portfolio and JustRight surgical stapler. The Skeletal Health segment's products include the Horizon DXA and the Fluoroscan Insight FD mini C-arm.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Hologic Scheduled to Announce Q4 Earnings on January 29th
- Earnings Announcement Date: Hologic (HOLX) is set to release its Q4 fiscal year 2023 earnings on January 29th after market close, with consensus EPS estimate at $1.10, reflecting a 2.7% year-over-year decline, and revenue estimate at $1.07 billion, indicating a 1.9% year-over-year increase.
- Historical Performance: Over the past two years, Hologic has consistently beaten EPS estimates 100% of the time and revenue estimates 75% of the time, demonstrating strong execution in financial forecasting.
- Estimate Revision Trends: In the last three months, EPS estimates have seen five upward revisions and no downward adjustments, while revenue estimates experienced four upward revisions and one downward, indicating growing market confidence in the company's future performance.
- Challenges and Opportunities: Despite facing challenges in product shipments for 2026, Hologic reported a non-GAAP EPS of $1.13, exceeding expectations by $0.03, and revenue of $1.05 billion, surpassing estimates by $20 million, showcasing the company's resilience in maintaining profitability amid adversity.
Continue Reading
Hologic Q4 Earnings Miss Expectations with Flat Revenue
- Earnings Miss: Hologic reported a Q4 non-GAAP EPS of $1.04, missing expectations by $0.06, indicating pressure on profitability that could undermine investor confidence.
- Flat Revenue: The company’s Q4 revenue stood at $1.05 billion, flat year-over-year but $20 million below market expectations, reflecting weak market demand that may impact future growth strategies.
- Challenging Outlook: Hologic indicated that the outlook for 2026 is more challenging due to halted product shipments, which could lead to a decline in market share, necessitating a reassessment of product lines and market strategies to address these challenges.
- Analyst Rating Watch: Following the earnings miss, analysts' quant ratings on Hologic may be affected, prompting investors to monitor subsequent rating changes to adjust their investment strategies.
Continue Reading